REMINDER: Our user survey closes on Friday, please submit your responses here.
https://www.bbc.co.uk/news/health-47553534
As understanding of cancer increases, it is all heading in the direction of personalised medicine based on an understanding of which type of cancer a person has (the link talks about breast cancer being 11 different cancers based on one criteria, there are more if you subdivide by other useful criteria, and I suspect more still as knowledge advances) and how their cancer evolves and how their cancer reacts treatment. Helpful in all this to have cheap and easy tests that can find which cancers people have... which is where we come in :-)
As ever, proud to be a small part of this by being a shareholder.
The video ("take a tour") is pretty sexy http://www.acetrainingcentre.com.au/
Good to be in bed with this sort of people.
sexy... in bed... hmmm... cold shower for seeingtom...
Looks like Veoneer have included an outdated slide in the Jan 2019 presentation. It is titled "December 31, 2017"!!
Also, most of the stated "awarded" totals are less than the Q3 2018 totals and none are more. Veoneer have not had such a severe loos of business! They would have had to announce it and would not have included such a loss of business in the latest presentation without providing some explanation.
Great news. To those in the know, this RNS is really good stuff. To the casual observer, it might be difficult to penetrate the technical language and understand the implications. Sometimes wonder where we'd be if we got The Sun to write the first paragraph of every RNS!
Rereading what I've posted, I don't wan you to take it the wrong way. it is not meant as an attack on you. I mean: If you are serious about helping other investors avoiding repeating YOUR mistakes, you need to be honest with them about the mistakes YOU made. So if you are serious, and not just a troll, it might be useful for them for you to do a bit of navel gazing and be honest about the mistakes you made.
Hey Woody
You do have my sympathy. I know you got annihilated on Flybe and you are lashing out. Do you have any money left to invest? Have you had any successful investments? Did you have all your eggs in the Flybe basket? Has that wiped you out?
It sounds like you made your Flybe investment purely based on what you read on the Flybe bulletin board and didn't do your research. Why did you fail to do your own research? Were you new to the investment game or did you just get lazy? Why did you put so much of your money at risk when you knew you hadn't done your research?
Hi All,
Anyone aware of an Assetco shareholder lawsuit against Grant Thornton? I was one of the many shareholders that they failed.
Thanks!
Thanks Jesterman.
Parsortix has multiple applications in multiple distinct markets so partnerships can be progressed in certain markets without detracting from potential for future partnerships in other markets.
For example, Angle say "discussions are in progress" with potential partners to develop the pre-natal testing market (NIPT) (a non-cancer market). Establishing such a partnership with the partner funding & managing the development (which I believe is Angle's basis for discussion) could be done without impacting future partnerships in cancer and would be a clever way of developing the NPIT market without distracting from the development of priority cancer markets. I believe the partner will be a very substantial organisation.
I also believe that, for the cancer markets directly impacted by the FDA trial in progress, partnership discussions will be held prior to FDA approval and may already be happening. Indeed, today's RNS talks of the development of existing partnerships and says "Additional corporate partnerships are being discussed for the Parsortix and HyCEAD Ziplex platforms". I think Angle will want to have their ducks in a row ready for FDA clearance and will want to minimise delay between FDA clearance and profiting from the area and benefiting patients. This may mean having agreements signed prior to FDA clearance or may mean having agreements negotiated and agreed awaiting signature on clearance. Just my view.
If, when I'm getting wound up, my car asks me if I want to hear some calming music, it'll get a beating!
https://www.youtube.com/watch?v=78b67l_yxUc
Unusually, Scotlouie, I completely disagree with you!
One point of disagreement is picky semantics: ALL share prices in EVERY company are based on speculation. Speculation: Noun: activity in which someone buys and sells things (such as stocks or pieces of property) in the hope of making a large profit but with the risk of a large loss. All investments have the risk of a large loss and a large gain , just some have higher or lower risks.
On a more serious point: I do not believe that FDA Approval will be the first trigger for a big shift upwards from the current share price. I think anyone who sits on the sides until then runs a big RISK of missing out. Potential triggers for large upwards shifts prior to FDA approval include:
1) FDA Study Completion
The FDA trial was designed in conjunction with the FDA and i would expect an RNS on or before submission telling us that the trial objectives have been met. If the FDA approved the trial and the objectives are met, then the risk of not getting FDA approval would seem low (but what do I know). For that reason, my guess would be there will be significant share price movement on submission (or prior), ie significant share price movement well before formal approval.
2) Non-Invasive Pre-Natal Testing
“The NIPT market is expected to reach $1.0 billion in market size by 2022. ANGLE plans to progress commercialisation of Parsortix in this market through commercial partnerships with one or more large healthcare companies. Discussions are in progress with a number of such companies.” I emphasise: Discussions are in progress. My understanding is that the “partner” will be completely footing the bill for developing and commercialising the technology. Imagine the impact on the shareprice if we RNS a partnership with Merck committing to develop and commercialise NPIT using Parsortix.
3) Awareness
We are seriously below the radar. Read the 10 Jan “Breakthrough” RNS again re clusters and the 29 Jan Lymph Node RNS-R. Both in the same month. I think this is amazing stuff and who knows if or when this will catapult into the mainstream press? What would the trigger be for general awareness? Another breakthrough research result? End of the FDA trial? Or just a slow news day? It is just not possible to predict if or when this will happen.
Obviously, this is not an exhaustive list. My guess is that there is a big rise coming but that the timing of the rise is unpredictable. However, I could be completely wrong.
If there are FDA delays, that will annoy me because i want the tech to be benefiting patients sooner, for their good. However, it won't worry me financially.
The FDA trial was designed in conjunction with the FDA and i would expect an RNS on or before submission telling us that the trial objectives have been met. If the FDA approved the trial and the objectives are met, then the risk of not getting FDA approval would seem low (but what do I know). For that reason, my guess would be there will be significant share price movement on submission (or prior), ie significant share price movement well before formal approval.
It is a possibility though most majors are denying it at the mo.
https://www.cnbc.com/2019/01/22/shutdown-leaves-drugmakers-in-dark-on-fda-approval-of-new-treatments.html
I am surprised that you have "no opinion on Angle as a company" especially given that you had a "close friend that died of cancer".
I am a very long term holder of Angle stock. It is currently my second largest investment and I love holding it and I read everything I can about what they are doing, including info published by Angle and published by others.
I too have personal reasons for being interested in cancer with someone very close currently going through terminal cancer. On that front, I am proud to be an investor in a company that could make a massive difference to improving the lot of future sufferers, even if it will sadly all come too late for my family member. Parsortix and associated advances together offer the hope of a revolution in diagnosis and treatment.
I am also an investor in pursuit of financial gain and the potential here is huge, in my humble opinion.
With my personal interest in cancer, and in making money, once I knew of Angle's existence and what they were up to, there was no way that I would not become an avid reader of all things Angle. And the more I read, the more I like.
If you are not interested in learning about Angle, given your background, you amaze me. If you have done your research, then you should have an opinion on Angle (good or bad, each to their own).
I appreciate that you feel you have been wronged by another one of your investments, and I can see that you are a little consumed by your emotional reaction to that unfortunate experience. I hope that, as the emotions come a little more under control, you'll find room in your life to read up on Angle. I have found it fascinating and uplifting and hope you do too.
https://www.redeye.se/themes/autotech/videos
Video "Redeye Autotech Seminar". At time 1:53:44
Veoneer say "USD$1bn order intake typically accumulates into USD$4bn-$6bn lifetime revenue".
Veoneer use Seeing Machines for DMS (see 1:49:51 in same video).
Worth remembering when looking at the value of RFQs mentioned in the RNS and the values of initial contracts already announced.
Good luck with your valiant fight Woodstock1970, liberator of men, savior of souls, champion of the down trodden. What would we all do without you?
By the way, I've got some eggs that need sucking but I'm not sure how to go about it. Please could you assist?
Who do you think we are?
Doddering old dears being fleeced by the big scary people?
Can you not trust us to do our own research and weigh up the risks for ourselves? Is that not the very least that should be expected of any investor? Do you disagree with the whole concept of shares being available to retail investors?